Assessment of drug resistance related genes as candidate markers for treatment outcome prediction of cutaneous leishmaniasis in Brazil

Acta Tropica

Volumn 126, Issue 2, 2013, Pages 132-141

  Torres, Davi Coe ^a   Ribeiro Alves, Marcelo ^b   Romero, Gustavo A S ^c   Dávila, Alberto M R ^a   Cupolillo, Elisa ^a  

^a INSTITUTO OSWALDO CRUZ   (Brazil)

^b Funda??o Oswaldo Cruz   (Brazil)

^c UNIVERSITY OF BRASILIA   (Brazil)

Author keywords

Cutaneous leishmaniasis; Leishmania braziliensis; Leishmania guyanensis; Molecular markers; Treatment failure

Indexed keywords

ADENINE; GUANINE; HEAT SHOCK PROTEIN 70; MEGLUMINE ANTIMONATE; THYMINE;

AMINO ACID; ANTIMONY; BIOMARKER; DISEASE TREATMENT; DRUG RESISTANCE; POLYMORPHISM; PUBLIC HEALTH;

AMINO ACID SEQUENCE; AQP1 GENE; ARTICLE; BRAZIL; CONTROLLED STUDY; DIAGNOSTIC VALUE; DRUG TREATMENT FAILURE; GENE MUTATION; GENETIC POLYMORPHISM; GENETIC VARIABILITY; HSP70 GENE; HUMAN; MARKER GENE; MOLECULAR GENETICS; MRPA GENE; NONHUMAN; NUCLEIC ACID BASE SUBSTITUTION; NUCLEOTIDE SEQUENCE; PARASITE ISOLATION; PREDICTION; PROGNOSIS; SKIN LEISHMANIASIS; TREATMENT OUTCOME; TRYR GENE; UNINDEXED SEQUENCE;

AMINO ACID SUBSTITUTION; ANIMALS; ANTIPROTOZOAL AGENTS; BASE SEQUENCE; BRAZIL; DNA, PROTOZOAN; DRUG RESISTANCE; GENETIC MARKERS; HSP70 HEAT-SHOCK PROTEINS; HUMANS; LEISHMANIA BRAZILIENSIS; LEISHMANIA GUYANENSIS; LEISHMANIASIS, CUTANEOUS; LEISHMANIASIS, MUCOCUTANEOUS; MEGLUMINE; MOLECULAR SEQUENCE DATA; MUTATION; ORGANOMETALLIC COMPOUNDS; POLYMORPHISM, GENETIC; PROGNOSIS; PROTOZOAN PROTEINS; SEQUENCE ANALYSIS, DNA; TREATMENT OUTCOME;

BRAZIL;

LEISHMANIA BRAZILIENSIS; LEISHMANIA GUYANENSIS;

EID: 84875534299     PISSN: 0001706X     EISSN: 18736254     Source Type: Journal    
DOI: 10.1016/j.actatropica.2013.02.002     Document Type: Article

References (59)

1. Abdo M.G., Elamin W.M., Khalil E.A., Mukhtar M.M. Antimony-resistant Leishmania donovani in eastern Sudan: incidence and in vitro correlation. East. Mediterr. Health J. 2003, 9:837-843.
2. Alvar J., Vélez I.D., Bern C., Herrero M., Desjeux P., Cano J., Jannin J., den Boer M. WHO Leishmaniasis Control Team, Leishmaniasis worldwide and global estimates of its incidence. PLoS One 2012, 7:e35671.
3. Arevalo J., Ramirez L., Adaui V., Zimic M., Tulliano G., Miranda-Verástegui C., Lazo M., Loayza-Muro R., De Doncker S., Maurer A., Chappuis F., Dujardin J.C., Llanos-Cuentas A. Influence of Leishmania (Viannia) species on the response to antimonial treatment in patients with American tegumentary leishmaniasis. J. Infect. Dis. 2007, 195:1846-1851.
4. Atkinson, E.J., Therneau, T.M., 2000. An introduction to recursive partitioning using the RPART routines. Technical report. Mayo Clinic Section of Biostatistics.
5. Azeredo-Coutinho R.B., Mendonça S.C., Callahan H., Portal A.C., Max G. Sensitivity of Leishmania braziliensis promastigotes to meglumineantimoniate (glucantime) is higher than that of other Leishmania species and correlates with response to therapy in American tegumentary leishmaniasis. J. Parasitol. 2007, l93:688-693.
6. Bonfante-Garrido R., Meléndez E., Barroeta S., de Alejos M.A., Momen H., Cupolillo E., McMahon-Pratt D., Grimaldi G. Cutaneous leishmaniasis in western Venezuela caused by infection with Leishmania venezuelensis and L. braziliensis variants. Trans. R. Soc. Trop. Med. Hyg. 1992, 86:141-148.
7. Breiman L. Random forests. Mach. Learn. 2001, 45:5-32.
8. Breiman L., Friedman J.H., Olshen R.A., Stone C.J. Classification and Regression Trees 1984, Wadsworth and Brooks, Pacific Grove, CA.
9. Brochu C., Haimeur A., Ouellette M. The heat shock protein HSP70 and heat shock cognate protein HSC70 contribute to antimony tolerance in the protozoan parasite Leishmania. Cell Stress Chaperones 2004, 9:294-303.
10. Calvopina M., Armijos R.X., Marco J.D., Uezato H., Kato H., Gomez E.A., Korenaga M., Barroso P.A., Mimori T., Cooper P.J., Nonaka S., Hashiguchi Y. Leishmania isoenzyme polymorphisms in Ecuador: relationships with geographic distribution and clinical presentation. BMC Infect. Dis. 2006, 6:139.
11. Carter K.C., Mullen A.B., Sundar S., Kenney R.T. Efficacies of vesicular and free sodium stibogluconate formulations against clinical isolates of Leishmania donovani. Antimicrob. Agents Chemother. 2001, 45:3555-3559.
12. Choudhuri S., Klaassen C.D. Structure, function, expression, genomic organization, and single nucleotide polymorphisms of human ABCB1 (MDR1), ABCC (MRP), and ABCG2 (BCRP) efflux transporters. Int. J. Toxicol. 2006, 25:231-259.
13. Clark L.A., Pregibon D. Tree-based models. Statistical Models in S 1993, 377-419. Chapman and Hall, London. J.M. Chambers, T.J. Hastie (Eds.).
14. Coelho A.C., Boisvert S., Mukherjee A., Leprohon P., Corbeil J., Ouellette M. Multiple mutations in heterogeneous miltefosine-resistant Leishmania major population as determined by whole genome sequencing. PLoS Negl. Trop. Dis. 2012, 6:e1512.
15. Croft S.L., Sundar S., Fairlamb A.H. Drug resistance in leishmaniasis. Clin. Microbiol. Rev. 2006, 19:111-126.
16. Cummings M.P., Segal M.R. Few amino acid positions in rpoB are associated with most of the rifampin resistance in Mycobacterium tuberculosis. BMC Bioinformatics 2004, 28(5):137.
17. Cupolillo E., Grimaldi G., Momen H. A general classification of New World Leishmania using numerical zymotaxonomy. Am. J. Trop. Med. Hyg. 1994, 50:296-311.
18. Cupolillo E., Grimaldi G., Momen H., Beverley S.M. Intergenic region typing (IRT): a rapid molecular approach to the characterization and evolution of Leishmania. Mol. Biochem. Parasitol. 1995, 73:145-155.
19. Cupolillo E., Momen H., Grimaldi G. Genetic diversity in natural populations of New World Leishmania. Memórias do Instituto Oswaldo Cruz 1998, 93:663-668.
20. Decuypere S., Vanaerschot M., Brunker K., Imamura H., Müller S., Khanal B., Rijal S., Dujardin J.C., Coombs G.H. Molecular mechanisms of drug resistance in natural Leishmania populations vary with genetic background. PLoS Negl. Trop. Dis. 2012, 6:e1514.
21. Delgado O., Cupolillo E., Bonfante-Garrido R., Silva S., Belfort E., Grimaldi G., Momen H. Cutaneous leishmaniasis in Venezuela caused by infection with a new hybrid between Leishmania (Viannia) braziliensis and L. (V.) guyanensis. Memórias do Instituto Oswaldo Cruz 1997, 92:581-582.
22. do Monte-Neto R.L., Coelho A.C., Raymond F., Légaré D., Corbeil J., Melo M.N., Frézard F., Ouellette M. Gene expression profiling and molecular characterization of antimony resistance in Leishmania amazonensis. PLoS Negl. Trop. Dis. 2011, 5:e1167.
23. Downing T., Imamura H., Decuypere S., Clark T.G., Coombs G.H., Cotton J.A., Hilley J.D., De Doncker S., Maes I., Mottram J.C., Quail M.A., Rijal S., Sanders M., Schönian G., Stark O., Sundar S., Vanaerschot M., Hertz-Fowler C., Dujardin J.C., Berriman M. Whole genome sequencing of multiple Leishmania donovani clinical isolates provides insights into population structure and mechanisms of drug resistance. Genome Res. 2011, 21:2143-2156.
24. Ewing B., Green P. Base-calling of automated sequencer traces using phred. II. Error probabilities. Genome Res. 1998, 8:186-194.
25. Ewing B., Hillier L., Wendl M.C., Green P. Base-calling of automated sequencer traces using phred. I. Accuracy assessment. Genome Res. 1998, 8:175-185.
26. Garcia A.L., Kindt A., Quispe-Tintaya K.W., Bermudez H., Llanos A., Arevalo J., Bañuls A.L., De Doncker S., Le Ray D., Dujardin J.C. American tegumentary leishmaniasis: antigen-gene polymorphism, taxonomy and clinical pleomorphism. Infect. Genet. Evol. 2005, 5:109-116.
27. Gordon D., Abajian C., Green P. Consed: a graphical tool for sequence finishing. Genome Res. 1998, 8:195-202.
28. Hadighi R., Mohebali M., Boucher P., Hajjaran H., Khamesipour A., Ouellette M. Unresponsiveness to glucantime treatment in Iranian cutaneous leishmaniasis due to drug-resistant Leishmania tropica parasites. PLoS Med. 2006, 3:e162.
29. Kelchner S.A. The evolution of non-coding chloroplast DNA and its application in plant systematics. Ann. Missouri Botanical Garden 2000, 87:482-498.
30. Kumar D., Singh R., Bhandari V., Kulshrestha A., Negi N.S., Salotra P. Biomarkers of antimony resistance: need for expression analysis of multiple genes to distinguish resistance phenotype in clinical isolates of Leishmania donovani. Parasitol. Res. 2012, 111:223-230.
31. Kumar A., Sisodia B., Misra P., Sundar S., Shasany A.K., Dube A. Proteome mapping of overexpressed membrane-enriched and cytosolic proteins in sodium antimony gluconate (SAG) resistant clinical isolate of Leishmania donovani. Br. J. Clin. Pharmacol. 2010, 70:609-617.
32. Larkin M.A., Blackshields G., Brown N.P., Chenna R., McGettigan P.A., McWilliam H., Valentin F., Wallace I.M., Wilm A., Lopez R., Thompson J.D., Gibson T.J., Higgins D.G. Clustal W and Clustal X version 2.0. Bioinformatics 2007, 23:2947-2948.
33. Laurent T., Rijal S., Yardley V., Croft S., De Doncker S., Decuypere S., Khanal B., Singh R., Schönian G., Kuhls K., Chappuis F., Dujardin J.C. Epidemiological dynamics of antimonial resistance in Leishmania donovani: genotyping reveals a polyclonal population structure among naturally resistant clinical isolates from Nepal. Infect. Genet. Evol. 2007, l7:206-212.
34. Leprohon P., Légaré D., Raymond F., Madore E., Hardiman G., Corbeil J., Ouellette M. Gene expression modulation is associated with gene amplification, supernumerary chromosomes and chromosome loss in antimony-resistant Leishmania infantum. Nucleic Acids Res. 2009, 37:1387-1399.
35. Librado P., Rozas J. DnaSP v5: a software for comprehensive analysis of DNA polymorphism data. Bioinformatics 2009, 25:1451-1452.
36. Lira R., Sunder S., Makharia A., Kenney R., Gam A., Saraiva E., Sack D. Evidence that high incidence of treatment failure in Indian kala-azar is due to the emergence of antimony resistant strains of Leishmania donovani. J. Infect. Dis. 1999, 180:564-567.
37. Llanos-Cuentas A., Tulliano G., Araujo-Castillo R., Miranda-Verastegui C., Santamaria-Castrellon G., Ramirez L., Lazo M., De Doncker S., Boelaert M., Robays J., Dujardin J.C., Arevalo J., Chappuis F. Clinical and parasite species risk factors for pentavalent antimonial treatment failure in cutaneous leishmaniasis in Peru. Clin. Infect. Dis. 2008, 46:223-231.
38. Louw C.A., Ludewig M.H., Mayer J., Blatch G.L. The Hsp70 chaperones of the Tritryps are characterized by unusual features and novel members. Parasitol. Int. 2010, 59:497-505.
39. Lupo J., Larrat S., Hilleret M.N., Germi R., Boyer V., Nicod S., Barguès G., Leroy V., Seigneurin J.M., Zarski J.P., Morand P. Assessment of selective real-time PCR for quantitation of lamivudine and adefovir hepatitis B virus-resistant strains and comparison with direct sequencing and line probe assays. J. Virol. Methods 2009, 156:52-58.
40. Machado P.R., Ampuero J., Guimarães L.H., Villasboas L., Rocha A.T., Schriefer A., Sousa R.S., Talhari A., Penna G., Carvalho E.M. Miltefosine in the treatment of cutaneous leishmaniasis caused by Leishmania braziliensis in Brazil: a randomized and controlled trial. PLoS Negl. Trop. Dis. 2010, 4:e912.
41. Mandal S., Maharjan M., Singh S., Chatterjee M., Madhubala R. Assessing aquaglyceroporin gene status and expression profile in antimony-susceptible and -resistant clinical isolates of Leishmania donovani from India. J. Antimicrob. Chemother. 2010, 65:496-507.
42. Modabber F., Buffet P.A., Torreele E., Milon G., Croft S.L. Consultative meeting to develop a strategy for treatment of cutaneous leishmaniasis. Institute Pasteur, Paris. 13-15 June, 2006. Kinetoplastid Biol. Dis. 2007, 6:3.
43. Neves L.O., Talhari A.C., Gadelha E.P., Silva R.M., Guerra J.A., Ferreira L.C., Talhari S. A randomized clinical trial comparing meglumine antimoniate, pentamidine and amphotericin B for the treatment of cutaneous leishmaniasis by Leishmania guyanensis. An. Bras. Dermatol. 2011, 86:1092-1101.
44. Oliveira-Neto M.P., Schubach A., Mattos M., Gonçalves-Costa S.C., Pirmez C. A low-dose antimony treatment in 159 patients with American cutaneous leishmaniasis: extensive follow-up studies (up to 10 years). Am. J. Trop. Med. Hyg. 1997, 57:651-655.
45. Ouellette M., Légaré D., Haimeur A., Grondin K., Roy G., Brochu C., Papadopoulou B. ABC transporters in Leishmania and their role in drug resistance. Drug Resist. Updat. 1998, 1:43-48.
46. R Development Core Team, 2010. R: A language and environment for statistical computing. R Foundation for Statistical Computing, Vienna, Austria. ISBN 3-900051-07-0, URL http://www.r-project.org/.
47. Rijal S., Yardley V., Chappuis F., Decuypere S., Khanal B., Singh R., Boelaert M., De Doncker S., Croft S., Dujardin J.C. Antimonial treatment of visceral leishmaniasis: are current in vitro susceptibility assays adequate for prognosis of in vivo therapy outcome?. Microb. Infect. 2007, 9:529-535.
48. Romero G.A., Guerra M.V.F., Paes M.G., Macêdo V.O. Comparison of cutaneous leishmaniasis due to Leishmania (Viannia) braziliensis and L. (V.) guyanensis in Brazil: therapeutic response to meglumine antimoniate. Am. J. Trop. Med. Hyg. 2001, 65:456-465.
49. Romero G.A., Ishikawa E., Cupolillo E., Toaldo C.B., Guerra M.V., Paes M.G., Macêdo V.O., Shaw J.J. Identification of antigenically distinct populations of Leishmania (Viannia) guyanensis from Manaus, Brazil, using monoclonal antibodies. Acta Trop. 2002, 82:25-29.
50. Rotureau B., Ravel C., Nacher M., Couppié P., Curtet I., Dedet J.P., Carme B. Molecular epidemiology of Leishmania (Viannia) guyanensis in French Guiana. J. Clin. Microbiol. 2006, 44:468-473.
51. Saravia N.G., Segura I., Holguin A.F., Santrich C., Valderrama L., Ocampo C. Epidemiologic, genetic, and clinical associations among phenotypically distinct populations of Leishmania (Viannia) in Colombia. Am. J. Trop. Med. Hyg. 1998, 59:86-94.
52. Strobl C., Boulesteix A.L., Zeileis A., Hothorn T. Bias in random forest variable importance measures: illustrations, sources and a solution. BMC Bioinformatics 2007, 8:25.
53. Teixeira A.C., Paes M.G., Guerra J., de O., Prata A., Silva-Vergara M.L. Failure of both azithromycin and antimony to treat cutaneous leishmaniasis in Manaus, AM, Brazil. Revista do Instituto de Medicina Tropical de São Paulo 2008, 50:157-160.
54. Torres D.C., Adaui V., Ribeiro-Alves M., Romero G.A., Arévalo J., Cupolillo E., Dujardin J.C. Targeted gene expression profiling in Leishmania braziliensis and Leishmania guyanensis parasites isolated from Brazilian patients with different antimonial treatment outcomes. Infect. Genet. Evol. 2010, 10:727-733.
55. Ubeda J.M., Légaré D., Raymond F., Ouameur A.A., Boisvert S., Rigault P., Corbeil J., Tremblay M.J., Olivier M., Papadopoulou B., Ouellette M. Modulation of gene expression in drug resistant Leishmania is associated with gene amplification, gene deletion and chromosome aneuploidy. Genome Biol. 2008, 9:R115.
56. Untergasser A., Nijveen H., Rao X., Bisseling T., Geurts R., Leunissen J.A.M. Primer3Plus, an enhanced web interface to Primer3. Nucleic Acids Res. 2007, 35:W71-W74.
57. Vanaerschot M., Decuypere S., Downing T., Imamura H., Stark O., De Doncker S., Roy S., Ostyn B., Maes L., Khanal B., Boelaert M., Schönian G., Berriman M., Chappuis F., Dujardin J.C., Sundar S., Rijal S. Genetic markers for SSG resistance in Leishmania donovani and SSG treatment failure in visceral Leishmaniasis patients of the Indian subcontinent. J. Infect. Dis. 2012, 206:752-755.
58. Vermeersch M., da Luz R.I., Toté K., Timmermans J.P., Cos P., Maes L. In vitro susceptibilities of Leishmania donovani promastigote and amastigote stages to antileishmanial reference drugs: practical relevance of stage-specific differences. Antimicrob. Agents Chemother. 2009, 53:3855-3859.
59. Walker J., Gongora R., Vasquez J.J., Drummelsmith J., Burchmore R., Roy G., Ouellette M., Gomez M.A., Saravia N.G. Discovery of factors linked to antimony resistance in Leishmania panamensis through differential proteome analysis. Mol. Biochem. Parasitol. 2012, 183:166-176.